AU Patent

AU2013204129C1 — Crystal Form of Quinoline Compound and Process for its Production

Assigned to Nissan Chemical Corp · Expires 2017-03-02 · 9y expired

What this patent protects

H:\dr\lntenvovn\NRPortbl\DCC\RBR\5067473_ .DOC- 1/04/2013 A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) 5 represented by the formula (1): The water content i…

USPTO Abstract

H:\dr\lntenvovn\NRPortbl\DCC\RBR\5067473_ .DOC- 1/04/2013 A method for producing a drug substance of crystalline pitavastatin calcium excellent in stability, is presented. In the production of a compound (pitavastatin calcium) 5 represented by the formula (1): The water content is adjusted to a level of from 5 to 15%, and the crystal form is controlled to be crystal form A, thereby to obtain a drug substance excellent in stability.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013204129C1
Jurisdiction
AU
Classification
—
Expires
2017-03-02
Drug substance claim
No
Drug product claim
No
Assignee
Nissan Chemical Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.